| 000 | 00942 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250517181839.0 | ||
| 264 | 0 | _c20190307 | |
| 008 | 201903s 0 0 eng d | ||
| 022 | _a1179-2027 | ||
| 024 | 7 |
_a10.1007/s40273-017-0537-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKarnon, Jonathan | |
| 245 | 0 | 0 |
_aHeath State Utility Values for Cost-Effectiveness Models. _h[electronic resource] |
| 260 |
_bPharmacoEconomics _c12 2017 |
||
| 300 |
_a1-3 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Introductory Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHealth Status |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 773 | 0 |
_tPharmacoEconomics _gvol. 35 _gno. Suppl 1 _gp. 1-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40273-017-0537-x _zAvailable from publisher's website |
| 999 |
_c27704536 _d27704536 |
||